Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CYP2C19 pharmacogenetics in advanced cancer: compromised function independent of genotype.

British journal of cancer - 21 Oct 2008

Helsby N A, Lo W-Y, Sharples K, Riley G, Murray M, Spells K, Dzhelai M, Simpson A, Findlay M

Abstract excerpt

CYP2C19 is a drug-metabolising enzyme involved in the metabolism of a number of chemotherapeutic agents including cyclophosphamide. Variants of the CYP2C19 gene result in a loss of function polymorphism, which affects approximately 3% of the Caucasian population. These individuals are poor metabolisers (PM) of a wide range of medications including omeprazole (OMP). In healthy subjects PM can be identified through...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Anti-Ulcer Agents
Share to Aryl Hydrocarbon Hydroxylases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C19

Share to Neoplasms

Share to Omeprazole

Share to Polymerase Chain Reaction

Share to Polymorphism, Restriction Fragment Length

Source

Open in PubMed Open full text

Identifiers

PMID: 18854824
DOI: 10.1038/sj.bjc.6604699
PMCID: PMC2570511

Genes

OMP

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CYP2C19 pharmacogenetics in advanced cancer: compromised function independent of genotype.PMID 18854824Read ↗

A discordance of the cytochrome P450 2C19 genotype and phenotype in patients with advanced cancer.Semantic proximity Read ↗

CYP2C19 genotype-phenotype discordance in patients with multiple myeloma leads to an acquired loss of drug-metabolising activity.Semantic proximity Read ↗

High CYP2C19 phenotypic variability in gastrointestinal cancer patients.Semantic proximity Read ↗

Identification and functional characterization of new potentially defective alleles of human CYP2C19.Semantic proximity Read ↗

Pheno- or genotype for the CYP2C19 drug metabolism polymorphism: the influence of disease.Semantic proximity Read ↗

CYP2C19 genotype and phenotype determined with omeprazole in patients with acid-related disorders with and without Helicobacter pylori infection.Semantic proximity Read ↗

CYP2C19 genotype and phenotype determined by omeprazole in a Korean population.Semantic proximity Read ↗

Novel mutations in the cytochrome P450 2C19 gene: a pitfall of the PCR-RFLP method for identifying a common mutation.Semantic proximity Read ↗

Genetic polymorphism of (S)-mephenytoin 4'-hydroxylation in populations of African descent.Semantic proximity Read ↗

Evaluation of predictive CYP2C19 genotyping assays relative to measured phenotype in a South African cohort.Semantic proximity Read ↗

Allelic, genotypic and phenotypic distributions of S-mephenytoin 4'-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world.Semantic proximity Read ↗

Determination of CYP2C19 phenotype in black Americans with omeprazole: correlation with genotype.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.